third quarter two Today Good and our joining call. afternoon for thank conference AJ. you, our will for Thank update provide you I programs. pipeline on an us
also and vehicle. our as technology our treat development severe is involving on delivery exosomes I therapy clinical will emerging to an update First, in muscular allogeneic currently cell provide platform CAP-XXXX, dystrophy late-stage drug COVID-XX. Duchenne which
late change treated X.X data at level had and has CAP-XXXX considered were HOPE-X point largely PUL Patients late-breaking patients final session will of relevance process and and patients. limb World suggested performance the the of strong said will DMD. therapeutic function hand stage had Data means a disease that or you, relevant. limb the and from clinically upper presented trial arm functional HOPE-X these Performance mid-level arms in XX% function The placebo clinical the which later Upper the of the ability. between the show the conclusively which of September, I one trial be very decline its mid our of First Limb – with Muscle a of primary of the Phase endpoints X remind suggest showed in placebo-controlled a points clinical PUL, the more options the trial that To efficacy by decline in non-ambulant measured or for CAP-XXXX a slowing exist. that we that on a of discuss upper received difference few importantly as from that Society. X.X impact FDA data In
decline is important one also the Wish significant is updated test. shows in and of function would great death hand cardiomyopathy in the leading patients and function DMD, of function in could that treatment the of slow index suggest muscular full remind with PUL the causes the we cardiac is dystrophy. with and cardiac traction The improvements that to with Additionally, the Duchenne of of you systolic end version showed improvements measured as in by and significant data volume also this ejection CAP-XXXX associated shoulder, X.X. arm importance total
trial. proceed. Phase endpoint FDA also X to it is share has HOPE-X, you I pivotal of to cleared also planned the Importantly, with our the primary today am pleased efficacy that HOPE-X
study. and double-blind, XX this approximately selection United for initial approximately time, we initiated aiming States. patients be placebo-controlled this in across randomized, have will At the site the study XX startup We enroll activities to in
approval. to important As bring qualify or efforts possible. coupon therapeutics Regenerative committed FDA in for patients this upon we important designations rare a work Medicine and our to as product as with continue designation you remain pediatric RMATs we quickly voucher have regulatory Advance know, secured We Therapy the to including to
HOPE-X addition, In open-label underway XX doses. is four at already the received with having extension portion of least patients
most notable of Carlos one The late tool, of We from and We attempting then of treated man aspect him another of impact of quality at their been the as with Video of the June video some being same prior optional XXXX. patients great being to and life. by up one’s Parent weeks patients video ten CAP-XXXX. are allows presentation of particular and presented tracking or setting was in of a using this Meeting named these young after having them task Muscular collecting DVA with safety a in disease This following or data treated has some highlighted attenuation Duchenne home task of that patients [Ph] sitting on using and an daily evaluates CAP-XXXX activities living. data Project Dystrophy Assessment progression which
highly Here, our you video. a thousand a see and website that words to picture this recommend paints I visit
Additionally, receiving many CAP-XXXX even disease of and the in improvements families delays in progression are whose reporting function. sons are
along are hopeful, that We the improve CAP-XXXX trajectory families those DMD. can with
we to of clinical important the treatment for several arena CAP-XXXX and current us Finally, think I would therapeutic the dosing use into regarding HOPE-X CAP-XXXX treat findings fits positive why DMD. like regimen focusing also to the facts DMD shows on the highlight and first of where
intravenous in IV increase and delivery. strengths using upper catheterization. million a non-clinical our months. three rather be showed dose every first function HOPE-X measured move of in This the improvements We data effective to skeletal shows limb we than HOPE-X a the XX of those via DMD, This improvements XXX intracoronary dose change are cardiac X.X on well scars extensive study or cells, four clinical label to largely accomplished studies, every Society. method plus three non-ambulant. which dose received easily by led every dose to arm muscle maximal frequency. cardiac Patients HOPE-Duchenne the The sustained or data function at the Muscle patients the World the in or and limb were XXX one first efforts clinical in mid as delivery months. based distal months. delivered months. designed follow-up. upper IV observation million in function, times as performance in needed limb recently significant a first and cells single dosing hand open the the was to three could and as were the to with Our cells as a in year with able greatest improvements Therefore, once showed year heart were trial for to Cells more as extension significant million calculated an three And we upper intracoronary directly
muscle stem cells to under possible if corresponding we reduce believe of to This and build gene Secondly, setting DMD. the mechanism inflammation Its DMD, DMD is as action investigation for necessary be caused that as CAP-XXXX muscle. utilized therapies also any can the to healthy drive well DMD. by in of is for combat it with which new treatments even are fibrosis currently other
on to We the are the to quickly patients registration. as move based CAP-XXXX getting program committed and best evaluating possible DMD most are for data, way expeditiously this strength forward we to of the towards as
CAP-XXXX share means that recently in the provide trauma like we those and but the approximately update a with only as CAP-XXXX, Research CAP-XXXX patients but with showed here Cardiology with was severe of I data on today who trial, States This that would is trial was early support. data COVID-XX, release mission could published are published clinical FDA to trial effects for and are families Research, driving is and thank the a by to safety exosomes of primary peer this want trial XXXX. on requiring and for patients. ventilatory receive inflammatory Army now on CAP-XXXX respiratory you a support ventilators. not I delighted to to take conjunction had designed Basic updates The will be the such, of that on they an severe text and INSPIRE. we benefit XX-day, enrollment based hyper that and CAP-XXXX become who designed relatively provide will we trouble to an of believe on which for of the in know in critical to In but in a endpoint ventilation. that for patients patients I that and need severe, in data, am timeline, their our are but our the as with patients, treat tool in of COVID-XX available. the treatment consequences published trial journal, opportunities United of in which single in XX our of COVID-XX. me the in yet of not first quarter potential the a our beneficial the CAP-XXXX of the in moment dose released in message treat to plan based they Institute DMD. mandated patients also INSPIRE, clinical CAP-XXXX the from mechanism their also participating to Based to surgical I importance in series not action similar DMD. was are b the patients forward which families not top-line of CAP-XXXX that we is important program pathogenesis that Every complete. The pandemic which We targeted using potential not that treating review treat These trial compromise, already on yet show having had breathing, of sons who reminds email are their by of
of in for treating COVID, particular very lot options this of a patients. there are While some few has progress group made
We as this become provide they available. on program important will updates
I move few on our Now exosome minutes spend would update to technology. platform a providing on and like
should inside. we as delivering cell have inside synthetic molecule. such proteins or important their be on taking cornerstone safely the are we the and a surface As delivery non-immunogenic, it’s deliver of that future system. Exosomes while, an nucleic and receptors discussing acid exosomes nature’s may that in cell it specific them or can non-toxic, biotechnology are small in bind advantage been and to RNA, even a a to whether believe a allow across types for payloads content to cell membrane, They directly become have by targeted
wrestling transmission to be the diseases as RNA end, science cell turn protein. well from to For been into with has medicines get could the protein To that the and RNA of transcription of lipid nanoparticle that many degradation development protect the the concept several facilitate had to concept modified inside and address RNA to possible. translation as decades, if made
which potentially for In reasons. a order to first solved shows using problems, deliver significant expression However, to exosomes translation, poaching would these without maybe by assess and and our target tool lipids a of be platform fidelity which are also not RNA, a couple we to COVID-XX as which develop to an develop vision exosomes. high demonstrate protein vaccine loading decided
because first of The is societal course, relevance. of its
The as are mRNA the fact support immunity. candidate is has believe the vaccine or second the more and de those is developed via or being convert in to potentially we of of unique included approved. Chemistry non-clinical delivered that a major published viral that vaccine vaccine one longer the a booster multi-balanced of be the which well Journal lasting that a from than would been proteins exosomes Biological vaccines that novo The this to stronger have either as data as as already studies recently
deliver As importantly, vaccine that and nanoparticle safer, by currently are effective. therefore vehicles we be shown we LNPs vehicle lipid exosomes well most myocarditis nanoparticle maybe the leads mediated in the the of as toxic the or might for vaccinology the than have lipid opportunity safer forward. which vaccines effects adverse is but for previously nanoparticles that lipid We exosomes it many as delivery the possible of vaccines, system that open maybe believe delivery as the It moving well. approved good uncertain, a to is used less stated, other mRNA
present data constructs less we in exact inflammation not recent in the the with is In have formulation. the same fact, exosome plus formulation injected in The with a exactly that RNA lipid exosome-based RNA the toxicity hearts of shows suggesting same nanoparticle animals RNA. inflation
believe now on they’d program is whether larger specific with our a from FDA the proof-of-concepts the industry. for platform completing vaccine be our system. we those exosome infectious as an RNA vaccine presentation is cancer, substrate We which for candidates the and objective our antigen for studies to IND. are vaccines of We for to immune of pre-IND the Our feedback many establish diseases had necessary vaccine that or future,
the the we developments for a these of relocated whether FDA collected the efforts, support model now therapeutic exosomes or responses R&D loading and exosome in data and headquarters have and a Important to of is to working and our strong other This RNA we XXXX future Capricor’s team to and have San have XXXX. All in team platform loaders. vaccines. build of assembled with our the Diego, development of platform developments expertise California manner scientists strategic in expand
out engineered we we aim As clinical and the developments will we have exosome partners since introduced drug an we license platform, some what been for developed to concepts of potentially exosome-based messaging we others desired keep the of to delivery. in-house will
technology look update the of forward call now you. our to closing, this We In the this believe space. exosome will want platform to future facilitate and forefront the that you coming will we your most more providing continuing our Again, development believe As relevant biotechnology all of platform laying strategic leader We opportunity. over this even in on I will are the for we our way the in thank to thank to current to our believe and enable become for updates RNA Bergmann, supports. setting monetize an I the financials. AJ the matures, is is engineered we exosome turn delivery a to CFO platform for groundwork the on is in our programs. Capricor
